Glenmark Pharmaceuticals cash flow

Latest FY26
Cash from operations
₹3,445cr−₹828 cr in FY25
Capital spending
₹1,358cr+81.1% on FY25
Free cash flow
₹2,087cr−₹1,577 cr in FY25
Cash from financing
−₹2,709cr₹787 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—573486631611
—209207517350
—−41.3−43.9−17.3−22.8
—0.00.0−0.0−0.4
—−0.00.0−745−0.0
—26.8−9.25.06.8
—−380−69.1−343−286
—2,266373900760
—−0.0−2.4−7.10.0
—17.037.45560.0
Changes in working capital
—−752−451−514−375
—−1,751−1,420970−849
—−649156−518−16.8
—2,705−814−752166
—20.13.162.853.5
Cash from operating activities
2,5331,9851,39936.5868
—2,243−1,547746397
—4,228−1477821,266
—7836801,047641
—3,445−828−265625
Cash from investing activities
—1,358750898608
—0.00.00.057.2
—2.32.42.10.0
—0.00.016.56.0
—0.00.00.05.0
—−0.27367.10.0
—0.00.05,4500.0
—0.00.00.00.4
—41.542.117.222.8
—30.8−28.6−192−0.1
—−1,2832.14,369−528
Cash from financing activities
—0.80.01.20.0
—0.030.10.00.0
—−1,7161,3414811,163
—5301413,649686
—135122104107
—187191517312
—14170.4118137
—−2,709787−3,906−77.5
—−547−38.519819.4
—46.055.917.713.1
—−50117.421532.5
——1,6761,6581,443
Reference items
4,7974,5722,3511,1952,278
27.0%26.9%17.7%10.1%17.5%
2,0872,087−1,577−1,16417.6
—−294−564−5,038—
₹73.97₹73.97−₹55.89−₹41.24₹0.62
31.10×————
—2.53×−0.79×0.19×1.66×
—7836801,047641
—187191517312
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹64,906 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation611.3630.8486.0573.5—
+ Finance Costs349.6517.4207.1208.7—
+ Interest Income-22.8-17.3-43.9-41.3—
+ Dividend Income-0.4-0.00.00.0—
+ Fair Value (Gains) / Losses-0.0-745.00.0-0.0—
+ Share-based Payments6.85.0-9.226.8—
+ Unrealised FX (Gain) / Loss-286.2-342.6-69.1-380.4—
+ Other Non-cash Items760.1900.1373.12,266.1—
+ Other — Cash Effects are Investing / Financing0.0-7.1-2.4-0.0—
+ Other Reconciling Items0.0555.637.417.0—
Changes in Working Capital
+ Inventories-375.2-513.9-450.8-752.3—
+ Trade Receivables — Current-848.7969.5-1,420.3-1,750.5—
+ Other Current Assets-16.8-518.2156.2-648.9—
+ Trade Payables — Current166.2-751.8-813.82,704.6—
+ Provisions — Current53.562.83.120.1—
Cash from Operating Activities
Profit Before Tax (per I/S)868.536.51,399.21,984.72,532.6
+ Total Adjustments (incl. Working Capital)397.5745.6-1,546.72,243.3—
Cash from Operations (pre-tax)1,265.9782.0-147.54,228.0—
+ Income Taxes Paid640.51,047.5680.1783.0—
Cash from Operating Activities625.4-265.4-827.63,445.0—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)607.8898.4749.61,357.7—
+ Disp of Fixed Assets57.20.00.00.0—
+ Disp of Investment Property0.02.12.42.3—
+ Acq of Other Long-term Assets6.016.50.00.0—
+ Disp of Other Long-term Assets5.00.00.00.0—
+ Sale of Investments (Equity / Debt)0.07.1735.7-0.2—
+ Disp of Subsidiaries / Businesses (net)0.05,449.60.00.0—
+ Dividends Received — Investing0.40.00.00.0—
+ Interest Received — Investing22.817.242.141.5—
+ Other Inflows / (Outflows) — Investing-0.1-191.9-28.630.8—
Cash from Investing Activities-528.54,369.12.1-1,283.2—
Cash from Financing Activities
+ Proceeds from Issue of Shares0.01.20.00.8—
+ Buyback / Redemption of Own Shares0.00.030.10.0—
+ Proceeds from Borrowings1,163.2481.11,341.2-1,715.7—
+ Repayment of Borrowings685.93,649.5140.7530.0—
+ Payment of Lease Liabilities106.6104.4122.2135.4—
+ Interest Paid311.5516.8190.8187.4—
+ Dividends Paid136.6117.870.4141.0—
Cash from Financing Activities-77.5-3,906.1787.0-2,708.8—
Net Changes in Cash (pre-FX)19.4197.6-38.5-547.0—
+ Effect of FX Rate Changes on Cash13.117.755.946.0—
Net Changes in Cash32.5215.217.4-501.0—
Closing Cash1,443.01,658.31,675.7——
Reference Items
EBITDA2,278.41,195.32,351.44,572.44,796.7
EBITDA Margin %17.5410.1217.6526.9227.04
Free Cash Flow (CFO − Capex)17.6-1,163.8-1,577.22,087.32,087.3
Free Cash Flow to Equity—-5,037.7-564.3-294.3—
Free Cash Flow per Basic Share0.62-41.24-55.8973.9773.97
Price to Free Cash Flow————31.10
Cash Flow to Net Income1.660.19-0.792.53—
Cash Paid for Taxes640.51,047.5680.1783.0—
Cash Paid for Interest311.5516.8190.8187.4—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.